AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Ruijin Hospital | N=20 ➔ 60 | Not yet recruiting ➔ Recruiting

Enrollment change • Enrollment open • Oncology • Pancreatic Cancer • Solid Tumor

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Fujian Cancer Hospital

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P2 trial • Oncology • Solid Tumor

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

Adebrelimab combined with short-course radiotherapy and CAPOX as total neoadjuvant therapy for pMMR locally advanced rectal cancer: Interim results (ESMO-GI 2025) - P2 | "Treatment included SCRT (25 Gy/5 fractions), six cycles of CAPOX (oxaliplatin 130 mg/m2 on day 1; capecitabine 1000 mg/m2 BID on days 1–14), and Adebrelimab (1200 mg Q3W). Adebrelimab combined with SCRT and CAPOX achieved a notably higher pCR rate compared to historical SCRT-based TNT regimens, with acceptable toxicity and preserved surgical outcomes. These interim findings support the potential of PD-L1 blockade to enhance neoadjuvant response in pMMR LARC."

Clinical • Metastases • pMMR • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Nanjing Tianyinshan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1/2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=69 | Recruiting | Sponsor: Xiuping Ding

New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

HP-BTC-002: A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC (clinicaltrials.gov) - P2 | N=39 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis. (PubMed, Front Pharmacol) - "Immune checkpoint inhibitors (ICIs) combined with etoposide-platinum are recommended as the standard first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)...The drug combination patterns included ipilimumab, durvalumab, adebrelimab, atezolizumab, socazolimab, pembrolizumab, serplulimab, tislelizumab, toripalimab, durvalumab + tremelimumab, tiragolumab + atezolizumab, benmelstobart + anlotinib, bevacizumab + atezolizumab, anlotinib, bevacizumab in combination with chemotherapy...The toxicity of ICI + Antiangio + Chemo was acceptable but needed careful attention. These findings clarified the roles of ICIs and antiangiogenic agent-based treatment strategies in this population."

Journal • Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Shanghai Hansoh Biomedical Co., Ltd

New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=25 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=43 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) (clinicaltrials.gov) - P2/3 | N=840 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Breast Cancer • Oncology • Solid Tumor

SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=52 | Not yet recruiting | Sponsor: Henan Cancer Hospital | Initiation date: Mar 2025 ➔ Jun 2025

Trial initiation date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Jun Jia | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P2 trial • Gastric Cancer • Oncology • Solid Tumor

Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Zhangzhou Municipal Hospital

New P2 trial • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

2025 ASCO Rapid Oral Report | Hengrui's innovative drug Adebelimumab combined with the treatment of triple-negative breast cancer brain metastasis study results disclosed [Google translation] (Jiangsu Hengrui Press Release) - P2 | N=35 | NCT04303988 | "Adebelimumab combined with bevacizumab and cisplatin/carboplatin is expected to provide a new combination treatment option for patients with advanced triple-negative breast cancer brain metastases....The median follow-up time was 17.5 months, the confirmed CNS-ORR was 77.1% (27/35), the confirmed CNS-CBR was 80% (28/35), the CNS-PFS was 11.5 months (6.2-NR), the overall mPFS was 8.3 months (5.8-11.5), and the median OS was not yet mature. Subgroup analysis showed that in the PD-L1-negative (CPS < 1) population, CNS-PFS was 11.5 months, and in the PD-L1-positive (CPS ≥ 1) population, CNS-PFS had not yet been reached due to the small number of events; the overall PFS was 7.6 months and 10 months in the PD-L1-negative and positive populations, respectively."

P2 data • Triple Negative Breast Cancer

Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. (PubMed, PLoS One) - "This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen."

HEOR • Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor